换一批Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
第一作者：
Junfei,Jin
第一单位：
aLaboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University bChina-USA Lipids in Health and Disease Research Center, Guilin Medical University, Guilin, China cDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, USA.
作者：
医学主题词
苯胺化合物(Aniline Compounds);动物(Animals);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);细胞系, 肿瘤(Cell Line, Tumor);抗药性, 肿瘤(Drug Resistance, Neoplasm);药物协同作用(Drug Synergism);人类(Humans);肺肿瘤(Lung Neoplasms);MAP激酶信号系统(MAP Kinase Signaling System);男(雄)性(Male);小鼠(Mice);小鼠, 裸(Mice, Nude);分子靶向治疗(Molecular Targeted Therapy);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质c-akt(Proto-Oncogene Proteins c-akt);原癌基因蛋白质c-bcl-2(Proto-Oncogene Proteins c-bcl-2);随机分配(Random Allocation);胃肿瘤(Stomach Neoplasms);磺胺类(Sulfonamides);增量调节(Up-Regulation);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays);bcl-X蛋白质(bcl-X Protein)
DOI
10.1097/CAD.0000000000000561
PMID
28885267
发布时间
2019-12-10
基金项目
UL1 TR001450/TR/NCATS NIH HHS/United States
- 浏览13
Anti-cancer drugs
1141-1149页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
